Bronchoalveolar Tregs are associated with duration of mechanical ventilation in acute respiratory distress syndrome

Norton, Dustin L.; Ceppe, Agathe; Tune, Miriya K.; McCravy, Matthew; Devlin, Thomas; Drummond, M. Bradley; Carson, Shannon S.; Vincent, Benjamin G.; Hagan, Robert S.; Dang, Hong; Doerschuk, Claire M.; Mock, Jason R.

doi:10.1186/s12967-020-02595-3

Table 4 Immune mediators in plasma of participants on Day 0 and Day 3

From: Bronchoalveolar Tregs are associated with duration of mechanical ventilation in acute respiratory distress syndrome

Analyte (pg/mL)	Day 0 (n = 12)	Day 3 (n = 10)	Slow resolver Day 0 (n = 5)	Fast resolver Day 0 (n = 7)	Slow resolver Day 3 (n = 5)	Fast resolver Day 3 (n = 5)
TNFSF13	6511.0 ± 4772	2539.9 ± 2986	3366.3 ± 3113	8757.3 ± 4601	1657.4 ± 1626	3422.3 ± 3933
TNFSF13B	1630.7 ± 1725	726.4 ± 1102	631.4 ± 344	2344.4 ± 1987	233.0 ± 169	1219.8 ± 1448
TNFRSF8	889.5 ± 566	492.0 ± 465	757.5 ± 350	983.7 ± 693	497.8 ± 461	486.2 ± 523
sCD163	5729.0 ± 3578	2950.8 ± 3196	3813.6 ± 2540	7097.2 ± 3732	2189.3 ± 1468	3712.3 ± 4402
Chitinase-3-like 1	11,140.4 ± 3988 (n = 9)	5941.6 ± 5326 (n = 7)	9741.0 ± 6801 (n = 2)	12,301.3 ± 327 (n = 4)	2232.0 ± 3138 (n = 2)	5956.5 ± 8406.8 (n = 2)
gp130/IL-6RB	7730.6 ± 3091	4891.3 ± 4302	5633.0 ± 1964	9228.9 ± 2943	3858.6 ± 2332	5923.9 ± 5791
IFN-α2	78.6 ± 25	50.8 ± 27	74.7 ± 12	81.4 ± 32	54.8 ± 26	46.7 ± 31
IFN-β	118.3 ± 37	70.7 ± 44	106.2 ± 29	126.9 ± 42	71.5 ± 38	69.9 ± 55
IFN-γ	105.5 ± 37	64.7 ± 40	95.2 ± 18	112.9 ± 46	70.1 ± 38	59.2 ± 45
IL-2	158.3 ± 53	101.1 ± 66	154.1 ± 38	155.0 ± 62	105.6 ± 61	96.6 ± 77
sIL-6Rα	1424.5 ± 521	952.7 ± 759	1403.7 ± 796	1439.4 ± 274	874.2 ± 580	1031.1 ± 972
IL-8	72.2 ± 23	44.8 ± 23	69.1 ± 17	74.4 ± 27	48.6 ± 22	41.0 ± 26
IL-10	105.0 ± 48	60.0 ± 35	95.3 ± 23	111.9 ± 61	65.2 ± 31	54.7 ± 41
IL-11	201.5 ± 75	124.2 ± 82	193.1 ± 74	207.5 ± 82	135.0 ± 82	113.3 ± 89
IL-12 (p40)	167.8 ± 63	100.4 ± 65	152.6 ± 39	178.7 ± 77	107.9 ± 62	92.8 ± 74
IL-12 (p70)	33.9 ± 8	25.9 ± 10	35.4 ± 11	32.9 ± 7	29.4 ± 11	22.3 ± 10
IL-19	64.9 ± 15	45.5 ± 21	63.8 ± 9	65.6 ± 18	51.1 ± 20	41.8 ± 23
IL-20	104.9 ± 37	66.3 ± 37	98.9 ± 19	109.2 ± 47	71.3 ± 35	61.3 ± 42
IL-22	71.6 ± 14	51.6 ± 28	68.7 ± 9	73.6 ± 17	55.8 ± 25	47.4 ± 33
IL-26	110.3 ± 23	73.5 ± 44	104.6 ± 16	114.4 ± 27	81.0 ± 41	65.9 ± 51
IL-27	50.8 ± 14	37.5 ± 18	52.8 ± 11	49.3 ± 16	43.8 ± 19	31.2 ± 17
IL-28A/IFN-λ2	97.3 ± 37	62.6 ± 38	87.1 ± 17	104.6 ± 47	65.2 ± 34	60.0 ± 45
IL-29/IFN-λ1	51.6 ± 17	34.8 ± 19	48.2 ± 8	54.0 ± 22	39.5 ± 18	30.0 ± 20
IL-32	113.1 ± 32	76.1 ± 41	111.2 ± 25	114.5 ± 38	81.6 ± 39	70.6 ± 48
IL-34	81.9 ± 27	52.7 ± 29	80.3 ± 19	83.1 ± 33	57.8 ± 27	47.5 ± 34
IL-35	177.3 ± 72	97.9 ± 65	156.7 ± 48	192.0 ± 86	97.9 ± 56	97.9 ± 80
LIGHT/TNFSF14	93.9 ± 45	47.5 ± 33	67.4 ± 22	112.9 ± 48	47.8 ± 28	47.2 ± 42
MMP-1	203.8 ± 71	119.4 ± 79	180.9 ± 14	220.1 ± 92	128.7 ± 72	110.1 ± 93
MMP-2	1048.1 ± 1356	950.4 ± 1430	421.5 ± 200	1495.6 ± 1668	612.5 ± 791	1288.2 ± 1921
MMP-3	971.5 ± 862	715.7 ± 915	644.8 ± 441	1204.9 ± 1039	527.9 ± 539	903.4 ± 1228
Osteocalcin	339.3 ± 245	195.0 ± 209	169.1 ± 82	460.9 ± 253	162.2 ± 168	227.8 ± 261
Osteopontin	13,693.2 ± 2460	8409.0 ± 6188	12,455.5 ± 2979	14,577.3 ± 1729	9069.0 ± 5881	7748.9 ± 7106
Pentraxin	7618.4 ± 6430	2868.9 ± 2637	5515.3 ± 4217	9120.6 ± 7592	2189.9 ± 1897	3547.8 ± 3301
sTNF-R1	5070.8 ± 2934	3167.8 ± 3160	3474.5 ± 2432	6210.9 ± 2863	3450.4 ± 3366	2885.2 ± 3308
sTNF-R2	1625.5 ± 1000	934.4 ± 1062	1196.7 ± 808	1931.8 ± 1066	1046.5 ± 1128	822.3 ± 1111
TSLP	110.5 ± 46	61.5 ± 39	93.7 ± 31	122.4 ± 53	64.1 ± 35	58.8 ± 46
TWEAK/TNFSF12	149.7 ± 46	112.2 ± 76	134.5 ± 52	160.5 ± 42	109.6 ± 60	114.7 ± 98

Immune mediators were measured in plasma at Day 0 or 3 post-enrollment. Values are mean ± SD. Samples with values below the lower limit of quantitation (LLOQ) for the assay were removed from the analysis. The number of samples used for calculations (n) is noted in the column subheading, unless otherwise indicated in the individual cells when concentrations for the specific cytokine or chemokine sample fell below the LLOQ. Immune mediators in italics reached statistical significance between Day 0 and Day 3, P < 0.05. The immune mediators TNFSF13 and TNFSF13B demonstrated a significant difference between fast and slow resolvers (independent of day). TNFSF13, Chitinase-3-like 1, IFN-α2, IFN-β, IFN-γ, IL-2, IL-8, IL-10, IL-11, IL-12 (p40), IL-19, IL-20, IL-26, IL-32, IL-34, IL-35, TNFSF14, MMP-1, Osteopontin, and TLSP demonstrated a significant difference between concentrations of all participants between Day 0 and Day 3. For each mediator, repeated measure ANOVA was used to compare day 0 and 3, fast and slow resolvers, and interaction

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Journal of Translational Medicine

Contact us